2025 Financial Report

GAMIAN-Europe

GAMIAN-Europe

The voice of patients in mental health

www.gamian.eu

Operating Income



Operating Charges



-€94,112.10 recorded loss during 2025

Industry		
Company	**Funding**	**Percentage of Funding**
Boehringer Ingelheim International GmbH	153 585,00	26,34%
Teva Pharmaceuticals Europe BV	70 000,00	12,00%
Angelini Pharma S.p.A	50 000,00	8,57%
Janssens Pharmaceutica	41 190,00	7,06%
H. Lundbeck	20 000,00	3,43%
Jetbrains S.R.O.	3 150,00	0,54%
Daiichi Sankyo Europe GmbH	560,00	0,10%
MedEd-Link, Inc	225,00	0,04%
Servier Affaires Medicales	-6 400,00	-1,10%
Total Industry	332 310,00	56,99%
Non Industry		
Kings College (ASPIRE Project)	83 383,00	14,30%
UMCG	40 948,45	7,02%
Eurohealthnet	34 934,64	5,99%
Munster	27 164,32	4,66%
European alliance against depression	23 640,49	4,05%
Magyar Maltai Szeretetszolg egyes	12 801,45	2,20%
Hoschule Emden	10 000,00	1,71%
Stiftung Buro ECNP	8 600,00	1,47%
Instituto Europeo di Oncologia	5 967,00	1,02%
Membership	2 950,00	0,51%
Sosped Foundation	417,00	0,07%
Total Non Industry	250 806,35	43,01%

January - December 2025		
Operating income 2025	583 116,35	100%
Controle	-583 116,35	
	0,00	

GAMIAN-Europe
The Voice of Patients in Mental Health
www.gamian.eu
Avenue Marnix 17, 1000 Brussels, Belgium